相关实验视频

Updated: Jun 25, 2025

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

疫苗接种及其对COVID-19患者肺部参与的影响:印度的一项回顾性研究

Suhasini Balasubramaniam¹, Priyadarsini Bose², Pravin Kumar Raviganesh³

¹Radiodiagnosis, Government Stanley Medical College and Hospital, Chennai, IND.

|May 27, 2024

概括

接种COVID-19疫苗,包括CoviShield®和Covaxin®,可以显著减少患者的肺部参与. 这一发现支持对疫苗的信任和接种,以减轻大流行.

科学领域:

传染性疾病传染性疾病
公共卫生公共卫生
免疫学免疫学免疫学

背景情况:

由于COVID-19大流行,印度需要快速开发疫苗,印度生产CoviShield®和Covaxin®.
疫苗犹对广泛的COVID-19免疫接种工作构成了挑战.
了解疫苗对疾病严重程度的有效性对于公共卫生战略至关重要.

研究的目的:

评估COVID-19疫苗接种情况与感染患者肺部感染程度之间的关系.
提供证据来打击疫苗犹,并促进印度的疫苗接受.

主要方法:

印度奈的272名COVID-19患者的回顾性横截面研究 (2021年5月至7月).
被归类为接种疫苗 (CoviShield®或Covaxin®) 或未接种疫苗的患者.
通过CT胸部扫描评估的肺部感染;统计分析对不同组的严重程度进行了比较.

主要成果:

与未接种疫苗的患者 (34.8%) 相比,接种疫苗的患者的平均肺部参与率 (28%) 显着较低.
在CoviShield®和Covaxin®接受者之间没有发现肺部参与的显著差异.
结果表明,疫苗接种对重症肺病具有普遍的保护作用.

结论:

接种COVID-19疫苗有效地减少了患者肺部感染的严重程度.
保护性益处在不同类型和剂量的疫苗中是一致的.
研究结果强调了疫苗接种在管理COVID-19影响和支持持续免疫计划中的关键作用.

关键词:

在Covaxin的研究中,在COVID-19中,有很多人.覆盖着一个盾牌.印度印度印度印度肺部参与肺部参与这是SARS-CoV-2病毒.接种疫苗接种疫苗疫苗的犹疫苗的犹

更多相关视频

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Published on: December 23, 2022

相关概念视频

Vaccinations

Vaccinations

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...